BofA lowered the firm’s price target on West Pharmaceutical (WST) to $300 from $370 and keeps a Buy rating on the shares after “a solid finish to the year” and FY26 guidance ahead of expectations, reflecting accelerating non-GLP-1 HVP growth. Following the earnings and guidance, the firm updated its model and applies a lower multiple due to group compression.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical price target lowered to $340 from $355 at UBS
- West Pharmaceutical price target raised to $315 from $310 at Deutsche Bank
- West Pharmaceutical price target lowered to $265 from $325 at Barclays
- West Pharmaceutical Services Signals HVP‑Led Growth Ahead
- Buy Rating on West: Strong Non‑GLP‑1 Growth, Margin Expansion, and Regulatory Tailwinds Support 2026 Outlook